Estudo randomizado | Eficácia e segurança da difelikefalina em pacientes com prurido moderado a grave recebendo hemodiálise.
10 Mai, 2022 | 14:09h
Comentário no Twitter
This RCT found difelikefalin, a κ-opioid receptor agonist, improved moderate to severe pruritus in Japanese hemodialysis patients. Difelikefalin is expected to be a new option for the treatment of uremic pruritus in patients with end stage kidney disease. https://t.co/cXqNx4QIaS pic.twitter.com/7QdA9GoLwN
— JAMA Network Open (@JAMANetworkOpen) May 5, 2022